Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARTRK-2: Entrectinib in Solid Tumors with NTRK, ROS1, or ALK Rearrangements
NCT02568267Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2015
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of entrectinib in solid tumor, sponsored by Roche. Started Nov 2015; status: active, not recruiting.
02
Drugs
entrectinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02568267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02568267.